Page 14 - Immune Sciences News Today

- ALPN-303 uniquely binds BAFF and APRIL with high affinity, differentiating from related inhibitors including wild-type TACI-Fc's - - Ongoing phase 1 study demonstrates highly encouraging preliminary

- ALPN-303 uniquely binds BAFF and APRIL with high affinity, differentiating from related inhibitors including wild-type TACI-Fc’s - - Ongoing phase 1 study demonstrates highly encouraging... | June 1, 2022

Press release content from Business Wire. The AP news staff was not involved in its creation.

FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept in Combination with Pembrolizumab SEATTLE, Wash., - May 24, 2022 - Alpine Immune... | May 24, 2022

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.06), Fidelity Earnings reports. Alpine Immune Sciences had a negative net margin of 214.70% and a negative return on equity of 59.07%. […]

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.06), Fidelity Earnings reports. Alpine Immune Sciences had a negative return on equity of 59.07% and a negative net margin of 214.70%. NASDAQ […]

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.06), Fidelity Earnings reports. Alpine Immune Sciences had a negative return on equity of 59.07% and a negative net margin of 214.70%. NASDAQ:ALPN […]

Cerevel Therapeutics (NASDAQ:CERE – Get Rating) and Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations. Institutional and Insider Ownership 77.0% of Alpine Immune Sciences […]

Wall Street analysts expect that Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) will post sales of $13.35 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Alpine Immune Sciences’ earnings, with estimates ranging from $5.93 million to $20.00 million. Alpine Immune Sciences posted sales of $3.20 million in […]